CRISPR screen identifies new regulator of androgen receptor in prostate cancer
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, and the Fred Hutchinson Cancer Center have identified PTGES3, known as the third prostaglandin E synthase protein as an unexpected regulator of the androgen receptor. This discovery, published November 5 in Nature Genetics, not only redefines PTGES3’s biological role in regulating gene expression, but also reveals a promising new target for treating ...